. 2015 Mar 1;9(3):FC05–FC09. doi: 10.7860/JCDR/2015/11884.5677

[Table/Fig-4]:

Comparison of efficacy and tolerability measures between and within the treatment groups.

	Darifenacin			p-value	Trospium			p-value (comparison within the group)	p-value (comparison between 2 groups)
	Baseline	2 weeks	4 weeks		Baseline	2 weeks	4 weeks
	Mean ± SD	Mean ± SD	Mean ± SD		Mean ± SD	Mean ± SD	Mean ± SD
OABSS	9.87 ± 3.75	4.07 ± 3.21	4.07 ± 3.29	0.0005^* 1.000^† 0.0005^‡	9.27 ± 3.21	4.27 ± 3.70	4.00 ± 3.86	0.0005^* 0.063^† 0.0005^‡	2 weeks	0.952^•
OABSS	9.87 ± 3.75	4.07 ± 3.21	4.07 ± 3.29	0.0005^* 1.000^† 0.0005^‡	9.27 ± 3.21	4.27 ± 3.70	4.00 ± 3.86	0.0005^* 0.063^† 0.0005^‡	4 weeks	0.654^•
Bristol stool consistency	2.60 ± 0.97	2.87 ± 0.82	2.47 ± 0.97	0.021^* 0.032^† 0.566^‡	3.07 ± 0.87	3.20 ± 1.24	3.20 ± 1.24	0.076^§	2 weeks	0.227^•
Bristol stool consistency	2.60 ± 0.97	2.87 ± 0.82	2.47 ± 0.97	0.021^* 0.032^† 0.566^‡	3.07 ± 0.87	3.20 ± 1.24	3.20 ± 1.24	0.076^§	4 weeks	0.017^•
KESS questionnaire	3.73 ± 3.45	3.87 ± 4.65	5.27 ± 5.98	0.084^§	3.33 ± 4.41	4.20 ± 4.44	4.00 ± 4.56	0.053* 0.157^† 0.105^‡	2 weeks	0.858^•
KESS questionnaire	3.73 ± 3.45	3.87 ± 4.65	5.27 ± 5.98	0.084^§	3.33 ± 4.41	4.20 ± 4.44	4.00 ± 4.56	0.053* 0.157^† 0.105^‡	4 weeks	0.244^•
McMillan & Williams CAS	0.27 ± 0.58	0.80 ± 1.63	1.20 ± 2.01	0.032^* 0.063^† 0.007^‡	0.53 ± 1.17	1.13 ± 1.89	1.13 ± 1.89	0.011^* 1.000^† 0.011^‡	2 weeks	0.778^•
McMillan & Williams CAS	0.27 ± 0.58	0.80 ± 1.63	1.20 ± 2.01	0.032^* 0.063^† 0.007^‡	0.53 ± 1.17	1.13 ± 1.89	1.13 ± 1.89	0.011^* 1.000^† 0.011^‡	4 weeks	0.944^•

*For comparison between baseline and 2 weeks (Wilcoxon signed ranks test)

^†For comparison between 2weeks and 4 weeks (Wilcoxon signed ranks test)

^‡For comparison between baseline and 4 weeks (Wilcoxon signed ranks test)

^§For overall comparison between baseline, 2 weeks and 4 weeks (Friedman test)

^•Mann Whitney U-test